How much revenue does Bharat Immunologicals & Biologicals make?

Bharat Immunologicals & Biologicals reported 446.09 million INR in revenue for fiscal year 2023, down 43.1% from 783.88 million INR in fiscal year 2022.

What companies are similar to Bharat Immunologicals & Biologicals?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Parmax Pharma Limited (PARMAX.BO), Kabra Drugs Limited (KABRADG.BO), Vista Pharmaceuticals Limited (VISTAPH.BO), Gujarat Terce Laboratories Limited (GUJTERC.BO).

Bharat Immunologicals & Biologicals Corporation Limited (BIBCL.BO) Stock

About Bharat Immunologicals & Biologicals Corporation Limited

Bharat Immunologicals & Biologicals Corporation Limited, a biotechnology company, engages in the manufacture and sale of pharmaceutical products in India. It offers oral polio vaccines, zinc tablets, diarrhea management kits, and BIB sweet tablets. The company was incorporated in 1989 and is based in Bulandshahr, India.

At a glance

Bharat Immunologicals & Biologicals reported revenue of 446.09 million INR for fiscal year 2023, down 43.1% from fiscal year 2022, and net income of -166.39 million INR.

Figures from company filings; latest fiscal year ended March 31, 2023.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.